Eir Ventures invests in Dania Tx

Eir Ventures invests in Dania Tx

Venture forces invest millions in new type of treatment for particularly aggressive form of cancer A syndicate consisting of the Lundbeck Foundation BioCapital, EIR Ventures, EIFO and UCPH Ventures has just made an investment in the Danish biotech company Dania...
Eir Ventures celebrates 3 years anniversary

Eir Ventures celebrates 3 years anniversary

Eir Ventures celebrates 3 years anniversary. On July 10, 2020, Eir Ventures I was launched with the announcement of the first close of our fund. Since the launch, Eir Ventures have completed investments in 17 pioneering life science companies; 5 companies have taken...
Lovisa Backemar new Principal.

Lovisa Backemar new Principal.

Eir Ventures welcomes Lovisa Backemar as Principal in the Eir Ventures Team. Lovisa is a Medical Doctor and holds a PhD in clinical epidemiology from the Karolinska Institute. Prior to joining Eir Ventures, Lovisa served as Head of Business Development at the Swedish...
Eir invests in RAPP

Eir invests in RAPP

Eir Ventures are delighted to announce our most recent investment in RAPP. The company was founded in Sweden based on Professor Ulrica Nilsson’s research, offering an evidence-based, interactive, and patient-centric digital platform that addresses several needs in the...
Eir invests in GutCRINE

Eir invests in GutCRINE

Eir Ventures are delighted to announce our most recent investment in GutCRINE. The company is a pioneering spin out from Copenhagen University developing a new first in class therapy targeting metabolic and age-related diseases like obesity, type 2 diabetes,...
Eir Ventures invests in Henlez

Eir Ventures invests in Henlez

Henlez mission is to transform the management of skin conditions by using enzymes. Henlez’s pre-clinical lead development program, HEN-001, is an enzyme-based, topical application directed towards hidradenitis suppurativa (HS) – a highly stigmatizing and chronic...
Hoba Therapeutics raises EUR 23 million in a Series A to advance new drug candidate against chronic neuropathic pain

Eir Ventures invests in Hoba Therapeutics

Hoba Therapeutics is Danish biotech developing restorative treatments for pain, hearing loss, and sensory neuron disorders. HB-086 is under development  for the treatment of pain in multiple chronic neuropathic pain indications. HB-086 is a non-opioid compound with a...